Use of car and bite technology coupled with an ScFv from an antibody against human thymidine kinase 1 to specifically target tumors
Modified T-cells have paratopes against human TK1 epitopes, are made by producing monoclonal antibodies that are specific to TK1, creating chimeric antigen receptors (CARs) by fusion of the single-chain variable fragments (scFv) of the monoclonal antibodies to T-cell signalling domains, and transducing the CARs to the T-cells.
1. A chimeric antigen receptor (CAR) comprising a single-chain variable fragment (scFv) specific for TK1 operatively linked to a signaling domain.
2. The CAR of claim 1 , wherein the signaling domain is a leukocyte signaling domain.
3. The CAR of claim 1 , wherein the signaling domain is a T-cell signaling domain.
4. The CAR of claim 1 , wherein the signaling domain is a monocyte signaling domain.
5. The CAR of claim 1 , wherein the signaling domain is a human signaling domain.
6. The CAR of claim 1 , wherein the scFv is specific for the C-terminal of TK1.
7. A nucleic acid encoding a chimeric antigen receptor (CAR) comprising a single-chain variable fragment (scFv) specific for TK1 operatively linked to a signaling domain.
8. The nucleic acid of claim 7 , wherein the nucleic acid comprises SEQ ID NO: 1.